330 results found
Yerlikaya S, Djamgoz MBA, 2022, Oleamide, a Primary Fatty Acid Amide: Effects on Ion Channels and Cancer, BIOELECTRICITY, ISSN: 2576-3105
Djamgoz MBA, 2022, Combinatorial Therapy of Cancer: Possible Advantages of Involving Modulators of Ionic Mechanisms, CANCERS, Vol: 14
Qiu S, Fraser SP, Pires W, et al., 2022, Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine, CLINICAL & EXPERIMENTAL METASTASIS, ISSN: 0262-0898
Djamgoz MBA, 2022, Rosalind Franklin Society: Mary Ann Liebert Award in Science (2021), BIOELECTRICITY, Vol: 4, Pages: 133-133, ISSN: 2576-3105
Djamgoz MBA, Jentzsch V, 2022, Integrative management of pancreatic cancer (PDAC): emerging complementary agents and modalities, Nutrition and Cancer: an international journal, Vol: 74, Pages: 1139-1162, ISSN: 0163-5581
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. The standard first-line treatment for PDAC is gemcitabine chemotherapy which, unfortunately, offers only limited chance of a lasting cure. This review further evaluates the hypothesis that the effectiveness of gemcitabine can be improved by combining it with evidence-based complementary measures. Previously, supported by clinical trial data, we suggested that a number of dietary factors and nutraceuticals can be integrated with gemcitabine therapy. Here, we evaluate a further 10 agents for which no clinical trials have (yet) been carried out but there are promising data from in vivo and/or in vitro studies including experiments involving combined treatments with gemcitabine. Two groups of complementary agents are considered: Dietary factors (resveratrol, epigallocatechin gallate, vitamin B9, capsaicin, quercetin and sulforaphane) and nutraceutical agents (artemisinin, garcinol, thymoquinone and emodin). In addition, we identified seven promising agents for which there is currently only basic (mostly in vitro) data. Finally, as a special case of combination therapy, we highlighted synergistic drug combinations involving gemcitabine with “repurposed” aspirin or metformin. We conclude overall that integrated management of PDAC currently is likely to produce the best outcome for patients and for this a wide range of complementary measures is available.
Levin M, Djamgoz MBA, 2022, Bioelectricity: From Endogenous Mechanisms to Opportunities in Synthetic Bioengineering, BIOELECTRICITY, Vol: 4, Pages: 1-2, ISSN: 2576-3105
Fraser SP, Onkal R, Theys M, et al., 2022, Neonatal Na(V)1.5 channels: pharmacological distinctiveness of a cancer-related voltage-gated sodium channel splice variant, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 179, Pages: 473-486, ISSN: 0007-1188
Djamgoz MBA, 2022, Ion Transporting Proteins and Cancer: Progress and Perspectives., Rev Physiol Biochem Pharmacol, Vol: 183, Pages: 251-277, ISSN: 0303-4240
Ion transporting proteins (ITPs) comprise a wide range of ion channels, exchangers, pumps and ionotropic receptors many of which are expressed in tumours and contribute dynamically to the different components and stages of the complex cancer process, from initiation to metastasis. In this promising major field of biomedical research, several candidate ITPs have emerged as clinically viable. Here, we consider a series of general issues concerning the oncological potential of ITPs focusing on voltage-gated sodium channels as a 'case study'. First, we outline some key properties of 'cancer' as a whole. These include epigenetics, stemness, metastasis, heterogeneity, neuronal characteristics and bioelectricity. Cancer specificity of ITP expression is evaluated in relation to tissue restriction, splice variance, functional specificity and macro-molecular complexing. As regards clinical potential, diagnostics is covered with emphasis on enabling early detection. For therapeutics, we deal with molecular approaches, drug repurposing and combinations. Importantly, we emphasise the need for carefully designed clinical trials. We highlight also the area of 'social responsibility' and the need to involve the public (cancer patients and healthy individuals) in the work of cancer research professionals as well as clinicians. In advising patients how best to manage cancer, and live with it, we offer the following four principles: Awareness and prevention, early detection, specialist, integrated care, and psychological support. Finally, we highlight four key prerequisites for commercialisation of ITP-based technologies against cancer. We conclude that ITPs offer significant potential as regards both understanding the intricacies of the complex process of cancer and for developing much needed novel therapies.
Djamgoz MBA, 2021, Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer, INTERNATIONAL JOURNAL OF CANCER, Vol: 150, Pages: 1212-1213, ISSN: 0020-7136
Djamgoz MBA, Pchelintseva E, 2021, Mechanosensitive Ion Channels and Stem Cell Differentiation, BIOELECTRICITY, Vol: 3, Pages: 249-254, ISSN: 2576-3105
Djamgoz MBA, 2021, 3rd International Meeting on Cancer and Ion Channels September 16-18, 2021; Istanbul Medipol University, Kavacik, Istanbul, Turkey, BIOELECTRICITY, Vol: 3, Pages: 292-293, ISSN: 2576-3105
Fraser SP, Tesi A, Bonito B, et al., 2021, Potassium Channel Blockage and Invasiveness of Strongly Metastatic Prostate and Breast Cancer Cells, BIOELECTRICITY, Vol: 3, Pages: 215-220, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2021, Bioelectricity Is the Bridge Where Cancer Meets Neuroscience, BIOELECTRICITY, Vol: 3, Pages: 159-160, ISSN: 2576-3105
Lastraioli E, Fraser SP, Guzel RM, et al., 2021, Neonatal Nav1.5 protein expression in human colorectal cancer: immunohistochemical characterization and clinical evaluation, Cancers, Vol: 13, Pages: 1-14, ISSN: 2072-6694
Voltage-gated Na+ channels (VGSCs) are expressed widely in human carcinomas and play a significant role in promoting cellular invasiveness and metastasis. However, human tissue-based studies and clinical characterization are lacking. In several carcinomas, including colorectal cancer (CRCa), the predominant VGSC is the neonatal splice variant of Nav1.5 (nNav1.5). The present study was designed to determine the expression patterns and clinical relevance of nNav1.5 protein in human CRCa tissues from patients with available clinicopathological history. The immunohistochemistry was made possible by the use of a polyclonal antibody (NESOpAb) specific for nNav1.5. The analysis showed that, compared with normal mucosa, nNav1.5 expression occurred in CRCa samples (i) at levels that were significantly higher and (ii) with a pattern that was more delineated (i.e., apical/basal or mixed). A surprisingly high level of nNav1.5 protein expression also occurred in adenomas, but this was mainly intracellular and diffuse. nNav1.5 showed a statistically significant association with TNM stage, highest expression being associated with TNM IV and metastatic status. Interestingly, nNav1.5 expression co-occurred with other biomarkers associated with metastasis, including hERG1, KCa3.1, VEGF-A, Glut1, and EGFR. Finally, univariate analysis showed that nNav1.5 expression had an impact on progression-free survival. We conclude (i) that nNav1.5 could represent a novel clinical biomarker (‘companion diagnostic’) useful to better stratify CRCa patients and (ii) that since nNav1.5 expression is functional, it could form the basis of anti-metastatic therapies including in combination with standard treatments.
Phillips JA, Hutchings C, Djamgoz MBA, 2021, Clinical Potential of Nerve Input to Tumors: A Bioelectricity Perspective, BIOELECTRICITY, Vol: 3, Pages: 14-26, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2021, Call for Special Issue Papers: The Bioelectricity of Connective TissueCells and their Environments, BIOELECTRICITY, Vol: 3, Pages: 2-2, ISSN: 2576-3105
Firmenich L, Djamgoz MBA, 2020, Society of General Physiologists Symposium on "Ion Channels and Transporters in Immunity, Inflammation and Antitumor Immunity" (held online on September 11, 2020), BIOELECTRICITY, Vol: 2, Pages: 418-423, ISSN: 2576-3105
Hutchings C, Phillips JA, Djamgoz MBA, 2020, Nerve input to tumours: Pathophysiological consequences of a dynamic relationship, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, Vol: 1874, ISSN: 0304-419X
Jentzsch V, Davis JAA, Djamgoz MBA, 2020, Pancreatic Cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management, Cancers, Vol: 12, Pages: 1-62, ISSN: 2072-6694
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which comprises some 85% of all cases. Currently, this is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Commonly applied clinical therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest of the commonly occurring cancers. This review cultivates the hypothesis that the best management of PDAC would be possible by integrating ‘western’ clinical medicine with evidence-based complementary measures. Protecting the liver, where PDAC frequently first spreads, is also given some consideration. Overall, the complementary measures are divided into three groups: dietary factors, nutraceutical agents and lifestyle. In turn, dietary factors are considered as general conditioners, multi-factorial foodstuffs and specific compounds. The general conditioners are alkalinity, low-glycemic index and low-cholesterol. The multi-factorial foodstuffs comprise red meat, fish, fruit/vegetables, dairy, honey and coffee. The available evidence for the beneficial effects of the specific dietary and nutraceutical agents was considered at four levels (in order of prominence): clinical trials, meta-analyses, in vivo tests and in vitro studies. Thus, 9 specific agents were identified (6 dietary and 3 nutraceutical) as acceptable for integration with gemcitabine chemotherapy, the first-line treatment for pancreatic cancer. The specific dietary agents were the following: Vitamins A, C, D and E, genistein and curcumin. As nutraceutical compounds, propolis, triptolide and cannabidiol were accepted. The 9 complementary agents were sub-grouped into two with reference to the main ‘hallmarks of cancer’. Lifestyle factors covered obesity, diabetes, smoking, alcohol and exercise. An integrative treatment regimen was devised for the management of PDAC patients. This involved combining first-line gemcitabine chem
Djamgoz MBA, 2020, What Is Life? By Paul Nurse, BIOELECTRICITY, Vol: 2, Pages: 314-315, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2020, Bioelectricity: A Quick Reminder of a Fast-Advancing Discipline!, BIOELECTRICITY, Vol: 2, Pages: 208-209, ISSN: 2576-3105
Schofield Z, Meloni GN, Tran P, et al., 2020, Correction to ‘Bioelectrical understanding and engineering of cell biology’, Journal of the Royal Society Interface, Vol: 17, Pages: 1-1, ISSN: 1742-5662
Rizaner N, Uzun S, Fraser SP, et al., 2020, Riluzole: Anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, Vol: 127, Pages: 254-264, ISSN: 1742-7835
Schofield Z, Meloni GN, Tran P, et al., 2020, Bioelectrical understanding and engineering of cell biology, Journal of the Royal Society Interface, Vol: 17, Pages: 1-8, ISSN: 1742-5662
The last five decades of molecular and systems biology research have provided unprecedented insights into the molecular and genetic basis of many cellular processes. Despite these insights, however, it is arguable that there is still only limited predictive understanding of cell behaviours. In particular, the basis of heterogeneity in single-cell behaviour and the initiation of many different metabolic, transcriptional or mechanical responses to environmental stimuli remain largely unexplained. To go beyond the status quo, the understanding of cell behaviours emerging from molecular genetics must be complemented with physical and physiological ones, focusing on the intracellular and extracellular conditions within and around cells. Here, we argue that such a combination of genetics, physics and physiology can be grounded on a bioelectrical conceptualization of cells. We motivate the reasoning behind such a proposal and describe examples where a bioelectrical view has been shown to, or can, provide predictive biological understanding. In addition, we discuss how this view opens up novel ways to control cell behaviours by electrical and electrochemical means, setting the stage for the emergence of bioelectrical engineering.
Ribeiro M, Elghajiji A, Fraser SP, et al., 2020, Human breast cancer cells demonstrate electrical excitability, Frontiers in Neuroscience, Vol: 14, Pages: 1-10, ISSN: 1662-453X
Breast cancer is one of the most prevalent types of cancers worldwide and yet, its pathophysiology is poorly understood. Single-cell electrophysiological studies have provided evidence that membrane depolarization is implicated in the proliferation and metastasis of breast cancer. However, metastatic breast cancer cells are highly dynamic microscopic systems with complexities beyond a single-cell level. There is an urgent need for electrophysiological studies and technologies capable of decoding the intercellular signaling pathways and networks that control proliferation and metastasis, particularly at a population level. Hence, we present for the first time non-invasive in vitro electrical recordings of strongly metastatic MDA-MB-231 and weakly/non-metastatic MCF-7 breast cancer cell lines. To accomplish this, we fabricated an ultra-low noise sensor that exploits large-area electrodes, of 2 mm2, which maximizes the double-layer capacitance and concomitant detection sensitivity. We show that the current recorded after adherence of the cells is dominated by the opening of voltage-gated sodium channels (VGSCs), confirmed by application of the highly specific inhibitor, tetrodotoxin (TTX). The electrical activity of MDA-MB-231 cells surpasses that of the MCF-7 cells, suggesting a link between the cells’ bioelectricity and invasiveness. We also recorded an activity pattern with characteristics similar to that of Random Telegraph Signal (RTS) noise. RTS patterns were less frequent than the asynchronous VGSC signals. The RTS noise power spectral density showed a Lorentzian shape, which revealed the presence of a low-frequency signal across MDA-MB-231 cell populations with propagation speeds of the same order as those reported for intercellular Ca2+ waves. Our recording platform paves the way for real-time investigations of the bioelectricity of cancer cells, their ionic/pharmacological properties and relationship to metastatic potential.
Djamgoz MBA, 2020, Hyponatremia and Cancer Progression: Possible Association with Sodium-Transporting Proteins, BIOELECTRICITY, Vol: 2, Pages: 14-20, ISSN: 2576-3105
Djamgoz MBA, Levin M, 2020, Inaugural Issue, BIOELECTRICITY, Vol: 2, Pages: 1-1, ISSN: 2576-3105
Lee A, Fraser SP, Djamgoz MBA, 2019, Propranolol inhibits neonatal Nav1.5 activity and invasiveness of MDA-MB-231 breast cancer cells: Effects of combination with ranolazine, JOURNAL OF CELLULAR PHYSIOLOGY, Vol: 234, Pages: 23066-23081, ISSN: 0021-9541
Bugan I, Kucuk S, Karagoz Z, et al., 2019, Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate, PROSTATE CANCER AND PROSTATIC DISEASES, Vol: 22, Pages: 569-579, ISSN: 1365-7852
Djamgoz MBA, Fraser SP, Brackenbury WJ, 2019, In Vivo Evidence for Voltage-Gated Sodium Channel Expression in Carcinomas and Potentiation of Metastasis, CANCERS, Vol: 11
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.